Early Results From CMMI’s Rapid Cycle Innovation Program
Manish Tanna, M.D., president of Nephrology Associates of Northern Illinois and Indiana, describes testing whether changes in patient outreach can improve preventive care for CKD patients
Read More
I Trusted A Popular Supplement — It Shut Down My Liver
Here’s why we need stricter oversight, independent third-party testing, more rigorous research and a cultural shift in how we think about ‘natural’ remedies. The post I Trusted A Popular Supplement — It Shut Down My Liver appeared first on MedCity News.
4 Notable Health Tech Funding Announcements in December
Health tech companies made several major funding announcements in December. Here is a list of some of the biggest funding rounds. The post 4 Notable Health Tech Funding Announcements in December appeared first on MedCity News.
Prisons Routinely Ignore Guidelines on Dying Inmates’ End-of-Life Choices
Brian Rigsby was lying with his right wrist shackled to a hospital bed in Montgomery, Alabama, when he learned he didn’t have long to live. It was September 2023, and Rigsby, 46, had been brought to Jackson Hospital from an Alabama state prison 10 days earlier after complaining of pain and swelling in his abdomen….
Eroding ACA Enrollment Portends Higher Insurance Rates
Enrollment in the Affordable Care Act continues to erode as some customers struggle to make premium payments, with the declining numbers churning market uncertainty for insurers. In response, insurers are likely to raise rates again next year, following this year’s larger-than-typical hikes. Sign-ups were already down in January by about 1.2 million from last year’s…
A New Option for Long-Term Care Costs
Kelly Haggett figures that a mandatory surcharge added to Washington state’s payroll tax cost her about $500 last year. But she doesn’t really mind. “On a scale of 1 to 10 of my annoyance with taxes in general, this one is about a 2,” she said. “I see the benefits.” The small surcharge on wages…
AstraZeneca Secures China Rights to Anemia Drug, Buying FibroGen Unit in $160M Deal
FibroGen secured regulatory approvals for roxadustat in China and Europe, but the FDA rejected the drug and asked for another clinical trial. By selling its China business to AstraZeneca, FibroGen can focus on developing a prostate cancer drug and potentially resuming development of roxadustat in another indication. The post AstraZeneca Secures China Rights to Anemia…
The Front Door of Healthcare Isn’t What You Think: How the Patient Payment Experience Defines Loyalty
When paying for care becomes a source of frustration, patients feel the pain. When the process feels easier elsewhere, they’re more likely to look for a new provider. Getting these processes right isn’t just about convenience, it’s about preserving trust and strengthening long-term relationships with patients. The post The Front Door of Healthcare Isn’t What…
Are you ready for Open Enrollment?
Open Enrollment for 2025 Marketplace coverage starts November 1. Open Enrollment is right around the corner. Make sure you’re ready. Image Did you: Gather basic information (PDF, 163 KB)? You can fill out your application faster if you’re ready with information like birthdates and Social Security Numbers (SSNs).Check to see if you might save on…
57 new drugs were approved in 2024
That is according to the FDA. Nature Reviews Drug Discovery summarizes the progress to date as follows. The FDA’s Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) approved 57 new therapeutic drugs (NTD) in 2024. This is slightly above the average of 53 NTDs per year for 2014–2024,…